home / stock / apre / apre quote
Last: | $ |
---|---|
Change Percent: | -0.29% |
Open: | $34.88 |
Close: | $34.52 |
High: | $36.00 |
Low: | $34.11 |
Volume: | 25,629 |
Last Trade Date Time: | 02/12/2020 04:44:03 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $34.88 | $34.52 | $36.00 | $34.11 | 25,629 | 02-12-2020 |
$ | $34.96 | $34.62 | $36.895 | $34.41 | 41,841 | 02-11-2020 |
$ | $35.35 | $34.80 | $36.25 | $34.06 | 46,652 | 02-10-2020 |
$ | $36.31 | $35.11 | $37.42 | $34.04 | 61,776 | 02-07-2020 |
$ | $38.15 | $36.02 | $38.37 | $35.01 | 56,377 | 02-06-2020 |
$ | $39.37 | $37.96 | $39.37 | $37.185 | 42,989 | 02-05-2020 |
$ | $39.63 | $38.48 | $39.7855 | $37.12 | 67,950 | 02-04-2020 |
$ | $39.27 | $39.50 | $39.93 | $37.48 | 73,734 | 02-03-2020 |
$ | $37.42 | $38.34 | $38.73 | $36.60 | 65,042 | 01-31-2020 |
$ | $38.97 | $37.23 | $38.97 | $36.2884 | 73,125 | 01-30-2020 |
$ | $35.76 | $35.85 | $36.8148 | $34.00 | 90,899 | 01-29-2020 |
$ | $38.12 | $35.94 | $38.97 | $35.31 | 122,631 | 01-28-2020 |
$ | $37.95 | $37.84 | $38.78 | $36.18 | 102,327 | 01-27-2020 |
$ | $40.51 | $38.58 | $40.74 | $38.40 | 83,992 | 01-24-2020 |
$ | $39.87 | $40.34 | $40.6645 | $38.48 | 62,502 | 01-23-2020 |
$ | $39.68 | $40.00 | $40.25 | $38.45 | 118,744 | 01-22-2020 |
$ | $39.45 | $38.83 | $39.94 | $38.49 | 68,442 | 01-21-2020 |
$ | $42.18 | $39.48 | $42.7725 | $39.03 | 61,389 | 01-20-2020 |
$ | $42.18 | $39.48 | $42.7725 | $39.03 | 61,387 | 01-17-2020 |
$ | $40.53 | $42.46 | $43.24 | $38.365 | 106,992 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Aprea Therapeutics Inc. Company Name:
APRE Stock Symbol:
NYSE Market:
Aprea Therapeutics Inc. Website:
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL...
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represent...
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been fo...